UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation
  • Publication Type:
    Journal article
  • Authors:
    Gafson AR, Jiang X, Shen C, Kapoor R, Zetterberg H, Fox RJ, Belachew S
  • Publisher:
    American Medical Association (AMA)
  • Publication date:
    08/02/2022
  • Journal:
    JAMA Network Open
  • Volume:
    5
  • Issue:
    2
  • Article number:
    e2147588
  • Medium:
    Electronic
  • Status:
    Published
  • Country:
    United States
  • PII:
    2788845
  • Language:
    English
  • Notes:
    This is an open access article distributed under the terms of the CC-BY-NC-ND License. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Abstract
Introduction Efforts to explore the utility of neurofilament light (NfL) as a biomarker associated with disability progression in multiple sclerosis (MS) have accelerated in recent years in the absence of pharmacodynamic or treatment response markers for clinical trials or patient care.1 The International Progressive MS Alliance stated in 2020 that serum NfL (sNfL) measurements may serve as a useful biomarker associated with progressive MS, although further work is needed to define the relative contributions of inflammatory activity and neurodegeneration to longitudinal changes in disability and sNfL.2 Using data from a large clinical trial of patients with secondary progressive MS (a phase 3, randomized, double-blind, placebo-controlled trial exploring the effect of natalizumab on disease progression in participants with Secondary Progressive Multiple Sclerosis [ASCEND in SPMS]; NCT01416181), we investigated whether sNfL could be used as a dynamic biomarker associated with progressive MS disease course. That is, we investigated whether longitudinal changes in sNfL concentration were associated with disability progression measures in the absence of relapses and magnetic resonance imaging (MRI) evidence of inflammatory activity
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
UCL Queen Square Institute of Neurology
Author
Neurodegenerative Diseases
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by